FinancingCommenting on the financing of the offering, Dr. Michael Berendt, chief executive officer and chief scientist, declared: "This financing, along with our current cash reserves, allows us to focus on our primary goal, which is to file the BLA for MCNA in the first quarter of next year. There is a significant unmet medical need for new, non-surgical treatment options for patients who have failed BCG treatment, and we will do everything in our power to ensure that we advance MCNA toward commercialization in the U.S. Concurrently, we have initiated a partnering process, and are actively engaging with interested parties which share our excitement about the potential approval and commercialization of MCNA in the U.S. and globally." I think when Dr. Berendt writes about excitement from potential partners, I'm willing to bet that he will negotiate a good deal for BNC shareholders.